Moleculin Biotech Inc (MBRX)

Apr 21, 2025

Moleculin Biotech Releases Corporate Presentation Online - TipRanks

Apr 21, 2025

Apr 18, 2025

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 17, 2025

Moleculin Biotech’s Annamycin Highlighted at AACR 2025 - TipRanks

Apr 17, 2025

Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 | MBRX Stock News - GuruFocus

Apr 17, 2025

Apr 17, 2025

Moleculin Announces Acceptance of Abstract to be Presented - GlobeNewswire

Apr 17, 2025

Apr 17, 2025

Major Cancer Research Breakthrough: Moleculin's Annamycin Drug Combinations Study Heads to AACR 2025 - Stock Titan

Apr 17, 2025

Apr 10, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum - Investing.com Australia

Apr 10, 2025

Apr 09, 2025

Moleculin Biotech adjourns special meeting due to lack of quorum By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 07, 2025

Moleculin Reports Second Quarter 2023 Financial Results - Seeking Alpha

Apr 07, 2025

Apr 02, 2025

Moleculin Biotech doses first patient in Phase 3 MIRACLE trial - Yahoo Finance

Apr 02, 2025

Apr 02, 2025

Moleculin Biotech begins dosing subjects in trial of combination therapy for AML - Yahoo

Apr 02, 2025

Apr 01, 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance

Apr 01, 2025

Apr 01, 2025

Moleculin Biotech Begins Phase 3 MIRACLE Trial Dosing - TipRanks

Apr 01, 2025

Apr 01, 2025

Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial - MarketScreener

Apr 01, 2025

Apr 01, 2025

Breakthrough AML Treatment Enters Final Testing Phase: Moleculin Launches Pivotal Trial - Stock Titan

Apr 01, 2025

Mar 29, 2025

Moleculin, CNS, Global-e, Tenet, Summit: Trending by Analysts - MSN

Mar 29, 2025

Mar 28, 2025

What is HC Wainwright’s Estimate for MBRX FY2025 Earnings? - Defense World

Mar 28, 2025

Mar 27, 2025

Roth Capital Issues Optimistic Estimate for MBRX Earnings - Defense World

Mar 27, 2025

Mar 26, 2025

All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy - MSN

Mar 26, 2025

Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Rating Increased to Buy at Maxim Group - Defense World

Mar 26, 2025

Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (MBRX) - MSN

Mar 26, 2025

Mar 26, 2025

Moleculin Biotech (NASDAQ:MBRX) Upgraded at StockNews.com - Defense World

Mar 26, 2025

Mar 26, 2025

Maxim Group Upgrades Moleculin Biotech (LSE:0K2H) - Nasdaq

Mar 26, 2025

Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock By Investing.com - Investing.com Australia

Mar 25, 2025

Mar 25, 2025

H.C. Wainwright maintains $8 target on Moleculin Biotech stock - Investing.com

Mar 25, 2025

Mar 25, 2025

Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4 - Marketscreener.com

Mar 25, 2025

Mar 25, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025

Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ... - Yahoo Finance

Mar 25, 2025

Mar 25, 2025

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: P - GuruFocus

Mar 25, 2025

Mar 25, 2025

Moleculin Biotech (NASDAQ:MBRX) Receives Buy Rating from HC Wainwright - Defense World

Mar 25, 2025

Mar 24, 2025

Moleculin Biotech Advances Clinical Trials Amid Financial Losses - TipRanks

Mar 24, 2025

Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Earnings call transcript: Moleculin Biotech’s Q1 2025 updates on Anamycin trials - Investing.com

Mar 24, 2025

Mar 24, 2025

Moleculin Biotech Inc Reports Q4 Earnings: EPS of -$1.28, Revenue at $0 Million, Aligns with Analyst Estimates - GuruFocus

Mar 24, 2025

Mar 24, 2025

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025

Mar 24, 2025

Moleculin Biotech Shares Corporate Presentation Update - TipRanks

Mar 24, 2025

Mar 24, 2025

FDA-Optimized Phase 3 AML Trial: Moleculin Cuts Costs, Expands to Europe - Stock Titan

Mar 24, 2025

Mar 21, 2025

Moleculin Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025

Mar 21, 2025

Moleculin Biotech, Inc. SEC 10-K Report - TradingView

Mar 21, 2025

Mar 19, 2025

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast - GlobeNewswire

Mar 19, 2025

Mar 19, 2025

Moleculin Biotech Prepares to Unveil Critical 2024 Financial Performance - Stock Titan

Mar 19, 2025

Mar 18, 2025

Moleculin Biotech Inc expected to post a loss of $1.28 a shareEarnings Preview - TradingView

Mar 18, 2025